Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFSIM + Toripalimab vs EP/EC in Neuroendocrine Carcinoma
NCT03992911Phase 3Unknown
- Sponsor
- Peking University
- Start
- Jun 2019
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of simmitecan and toripalimab in neuroendocrine carcinoma (NEC) (2 arms), sponsored by Peking University. Primary endpoint: Overall Survival at 2 years. Status: unknown.
02
Drugs
simmitecantoripalimab
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT03992911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03992911.